Equities researchers at StockNews.com assumed coverage on shares of Acorda Therapeutics (NASDAQ:ACOR – Get Rating) in a report released on Monday. The brokerage set a "hold" rating on the biopharmaceutical company's stock.
Acorda Therapeutics Price Performance
Shares of ACOR stock opened at $0.29 on Monday. The company has a market cap of $7.06 million, a P/E ratio of -0.03 and a beta of 0.45. The company has a quick ratio of 1.49, a current ratio of 1.86 and a debt-to-equity ratio of 2.10. The business has a fifty day simple moving average of $0.42 and a 200 day simple moving average of $0.77. Acorda Therapeutics has a twelve month low of $0.28 and a twelve month high of $4.94.
Get
Acorda Therapeutics alerts:
Acorda Therapeutics (NASDAQ:ACOR – Get Rating) last posted its quarterly earnings data on Thursday, August 4th. The biopharmaceutical company reported ($2.78) earnings per share for the quarter, missing the consensus estimate of ($0.36) by ($2.42). Acorda Therapeutics had a negative return on equity of 90.29% and a negative net margin of 98.25%. The firm had revenue of $31.05 million for the quarter.
Institutional Trading of Acorda Therapeutics
Institutional investors and hedge funds have recently modified their holdings of the business. Prudential Financial Inc. bought a new position in shares of Acorda Therapeutics during the 2nd quarter valued at $28,000. Virtu Financial LLC purchased a new position in Acorda Therapeutics during the second quarter valued at $68,000. Millennium Management LLC grew its holdings in Acorda Therapeutics by 661.2% in the second quarter. Millennium Management LLC now owns 311,509 shares of the biopharmaceutical company's stock worth $145,000 after purchasing an additional 270,588 shares during the period. Finally, Renaissance Technologies LLC raised its stake in Acorda Therapeutics by 27.4% during the second quarter. Renaissance Technologies LLC now owns 901,318 shares of the biopharmaceutical company's stock valued at $420,000 after buying an additional 194,100 shares during the last quarter. Hedge funds and other institutional investors own 50.24% of the company's stock.
About Acorda Therapeutics
(Get Rating)
Acorda Therapeutics, Inc, a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); and Inbrija for the treatment of OFF periods in Parkinson's disease in Europe.
Further Reading
- Get a free copy of the StockNews.com research report on Acorda Therapeutics (ACOR)
- Defensive Stocks For A Volatile Market
- SunPower Is Ready To Power Up Triple-Digit Earnings Gains
- Will UPS Be Next to Deliver a Warning?
- Is This the Darkest Before the Dawn for Gap Stock?
- Build A Better Tech Portfolio With Jabil Inc.
Receive News & Ratings for Acorda Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acorda Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
Equities researchers at StockNews.com assumed coverage on shares of Acorda Therapeutics (NASDAQ:ACOR – Get Rating) in a report released on Monday. The brokerage set a "hold" rating on the biopharmaceutical company's stock.
StockNews.com的股票研究人员在周一发布的一份报告中假设了阿科达治疗公司(纳斯达克:ACOR-GET Rating)的股票报道。该经纪公司对这家生物制药公司的股票设定了“持有”评级。
Acorda Therapeutics Price Performance
Shares of ACOR stock opened at $0.29 on Monday. The company has a market cap of $7.06 million, a P/E ratio of -0.03 and a beta of 0.45. The company has a quick ratio of 1.49, a current ratio of 1.86 and a debt-to-equity ratio of 2.10. The business has a fifty day simple moving average of $0.42 and a 200 day simple moving average of $0.77. Acorda Therapeutics has a twelve month low of $0.28 and a twelve month high of $4.94.
周一,ACOR股票开盘报0.29美元。该公司市值为706万美元,市盈率为-0.03,贝塔系数为0.45。该公司的速动比率为1.49,流动比率为1.86,债务权益比为2.10。该业务的50日简单移动均线为0.42美元,200日简单移动均线为0.77美元。Acorda Treeutics的12个月低点为0.28美元,12个月高位为4.94美元。
Get
Acorda Therapeutics
alerts:
Acorda Therapeutics (NASDAQ:ACOR – Get Rating) last posted its quarterly earnings data on Thursday, August 4th. The biopharmaceutical company reported ($2.78) earnings per share for the quarter, missing the consensus estimate of ($0.36) by ($2.42). Acorda Therapeutics had a negative return on equity of 90.29% and a negative net margin of 98.25%. The firm had revenue of $31.05 million for the quarter.
阿科达治疗公司(纳斯达克:ACOR-GET评级)上一次公布季度收益数据是在8月4日星期四。这家生物制药公司公布了本季度每股收益(2.78美元),低于普遍预期的(0.36美元)和(2.42美元)。阿科达治疗公司的净资产回报率为负90.29%,净利润率为负98.25%。该公司本季度的收入为3105万美元。
Institutional Trading of Acorda Therapeutics
Institutional investors and hedge funds have recently modified their holdings of the business. Prudential Financial Inc. bought a new position in shares of Acorda Therapeutics during the 2nd quarter valued at $28,000. Virtu Financial LLC purchased a new position in Acorda Therapeutics during the second quarter valued at $68,000. Millennium Management LLC grew its holdings in Acorda Therapeutics by 661.2% in the second quarter. Millennium Management LLC now owns 311,509 shares of the biopharmaceutical company's stock worth $145,000 after purchasing an additional 270,588 shares during the period. Finally, Renaissance Technologies LLC raised its stake in Acorda Therapeutics by 27.4% during the second quarter. Renaissance Technologies LLC now owns 901,318 shares of the biopharmaceutical company's stock valued at $420,000 after buying an additional 194,100 shares during the last quarter. Hedge funds and other institutional investors own 50.24% of the company's stock.
机构投资者和对冲基金最近调整了对该公司的持股。保诚金融公司在第二季度购买了价值28,000美元的Acorda Treateutics股票的新头寸。Virtu Financial LLC在第二季度购买了Acorda治疗公司的一个新头寸,价值6.8万美元。千禧管理有限责任公司在第二季度增持了661.2%的Acorda Treeutics股份。Millennium Management LLC现在拥有这家生物制药公司311,509股股票,价值145,000美元,在此期间又购买了270,588股。最后,复兴技术有限责任公司在第二季度将其在Acorda治疗公司的股份增加了27.4%。复兴科技有限责任公司现在持有这家生物制药公司901,318股股票,价值42万美元,在上个季度又购买了194,100股。对冲基金和其他机构投资者持有该公司50.24%的股票。
About Acorda Therapeutics
Acorda Therapeutics, Inc, a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); and Inbrija for the treatment of OFF periods in Parkinson's disease in Europe.
Acorda治疗公司是一家生物制药公司,在美国开发和销售神经疾病的治疗方法。该公司在欧洲营销Ampyra(达法普利定),一种改善多发性硬化症(MS)患者行走能力的口服药物;以及Inbrija,用于治疗帕金森病的间歇期。
Further Reading
- Get a free copy of the StockNews.com research report on Acorda Therapeutics (ACOR)
- Defensive Stocks For A Volatile Market
- SunPower Is Ready To Power Up Triple-Digit Earnings Gains
- Will UPS Be Next to Deliver a Warning?
- Is This the Darkest Before the Dawn for Gap Stock?
- Build A Better Tech Portfolio With Jabil Inc.
- 免费获取StockNews.com关于Acorda治疗公司(ACOR)的研究报告
- 防御性股票应对动荡的市场
- SunPower准备推动三位数的收益增长
- UPS会成为下一个发出警告的公司吗?
- 这是Gap Stock黎明前最黑暗的一次吗?
- 与捷普公司一起打造更好的技术产品组合。
Receive News & Ratings for Acorda Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acorda Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
获得《Acorda治疗日报》的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对Acorda Treateutics和相关公司的最新新闻和分析师评级的每日简要摘要。